

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) hereby announces that a meeting of the Board will be held on Tuesday, 24 March 2026, for the purposes of, among other things, considering and approving the final results of the Company and its subsidiaries for the year ended 31 December 2025, recommendation of a final dividend, if any, and transacting any other business.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

9 March 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee Director of the Company is Ms. Yan Jia.

* For identification purposes only